Synergistic Antitumor Effect of α-pinene and β-pinene with Paclitaxel against Non-small-cell Lung Carcinoma (NSCLC)

Abstract The objective of the present research work was to evaluate the synergistic interactions between Paclitaxel (PAC) with α-pinene and β-pinene using isobolographic method against non-small-cell lung cancer cells (NSCLC). This type of interaction between an established drug and a new compound is expected to enhance the efficacy of paclitaxel in combination as compared in isolation. Further, cell cycle analysis was carried out using flow cytometric analysis. Phase contrast microscopy was used to assess the effect of paclitaxel, α-pinene and β-pinene alone and in combination with each other in order to evaluate the effect of combination on cell apoptosis. Further, mitochondrial membrane potential was monitored in non-small-cell lung cancer cells (NSCLC) when treated with paclitaxel, α-pinene and β-pinene alone and in combination. The results revealed that the combination of PAC with α-pinene or with β-pinene showed a plotted curve below the straight line, generating a substantial synergistic effect. The effects of the following combinations were examined utilizing isobolograms: PAC and α-pinene and PAC and β-pinene. The combination of PAC and α-pinene as well as of PAC and β-pinene actually generated a synergistic effect. We also examined the effects of these compounds on the cell cycle distributions of A549 cells by flow cytometric analysis. The percentage of sub-G0/G1-phase cells was decreased on the addition of α-pinene to PAC, while the population of G0/G1 cells was increased. The morphological changes characteristic of apoptosis like chromatin condensation and fragmentation of the nucleus were seen in PAC+α-pinene and PAC+β-pinene treated NSCLC cells.

[1]  F. Geyikoğlu,et al.  Antioxidative, anticancer and genotoxic properties of α-pinene on N2a neuroblastoma cells , 2013, Biologia.

[2]  I. Cock.  The phytochemistry and chemotherapeutic potential of Tasmannia lanceolata (Tasmanian pepper): A review , 2013 .

[3]  M. Wink,et al.  Carotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters. , 2012, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[4]  S. Hill,et al.  Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer , 2012, PloS one.

[5]  R. Bast,et al.  The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. , 2011, Journal of the National Cancer Institute.

[6]  D. Wigle,et al.  Surgical management of lung cancer. , 2011, Seminars in respiratory and critical care medicine.

[7]  C. Rodríguez-Antona,et al.  Pharmacogenomics of paclitaxel. , 2010, Pharmacogenomics.

[8]  Y. Oda,et al.  Overexpression of Class III β-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma , 2009, Clinical Cancer Research.

[9]  Y. Zu,et al.  Antioxidative activity of Rosmarinus officinalis L. essential oil compared to its main components. , 2008, Food chemistry.

[10]  A. Ganti,et al.  Treatment options for relapsed small-cell lung cancer , 2007, Anti-cancer drugs.

[11]  G. Hernández‐Flores,et al.  In vitro Induction of Apoptosis in U937 Cells by Perillyl Alcohol with Sensitization by Pentoxifylline: Increased BCL-2 and BAX Protein Expression , 2006, Chemotherapy.

[12]  H. Gillenwater,et al.  Second-line treatment of small-cell lung cancer , 2006, Current oncology reports.

[13]  D. Fang,et al.  [Surgical therapeutic strategy for non-small cell lung cancer with (N2) mediastinal lymph node metastasis]. , 2006, Zhonghua zhong liu za zhi [Chinese journal of oncology].

[14]  Anthony J Alberg,et al.  Epidemiology of lung cancer: looking to the future. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Rotem,et al.  Jasmonates: novel anticancer agents acting directly and selectively on human cancer cell mitochondria. , 2005, Cancer research.

[16]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[17]  M. Gottesman.  Mechanisms of cancer drug resistance. , 2002, Annual review of medicine.

[18]  D. Waller.  Neoadjuvant chemotherapy in non small cell lung cancer-the UK experience. , 2001, Lung cancer.

[19]  D. Ukena.  Chemotherapy in stage I+II non-small cell lung cancer. , 2001, Lung cancer.

[20]  Hu Yong-xiao.  Clinical study of lymph node metastasis in lung cancer , 2000 .

[21]  M. Krasnik,et al.  [Neoadjuvant chemotherapy in non-small-cell lung cancer]. , 1999, Ugeskrift for laeger.

[22]  K. Picard,et al.  Monoterpenes inhibit cell growth, cell cycle progression, and cyclin D1 gene expression in human breast cancer cell lines. , 1998, Nutrition and cancer.

[23]  P. Huxley.  A UK experience. , 1998, Canadian journal of community mental health = Revue canadienne de sante mentale communautaire.

[24]  L. Peters,et al.  Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. , 1996, Journal of the National Cancer Institute.

[25]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.